Edition:
United States

People: Jounce Therapeutics Inc (JNCE.OQ)

JNCE.OQ on NASDAQ Stock Exchange Global Select Market

3.69USD
3:59pm EST
Change (% chg)

$-0.05 (-1.34%)
Prev Close
$3.74
Open
$3.79
Day's High
$3.79
Day's Low
$3.60
Volume
46,385
Avg. Vol
77,393
52-wk High
$29.02
52-wk Low
$3.31

Higgons, J. Duncan 

Mr. J. Duncan Higgons is an Independent Director of the Company. Mr. Higgons served as chief operating officer of Agios Therapeutics, Inc., or Agios, a public biopharmaceutical company, from 2009 to January 2016. Prior to joining Agios, Mr. Higgons served as executive vice-president, and interim president and chief executive officer at Archemix Corporation, or Archemix, from 2006 to 2009. Prior to Archemix, Mr. Higgons served as the chief commercial officer at TransForm Pharmaceuticals, Inc., which was acquired by Johnson & Johnson Company. Mr. Higgons serves on the board of PsiOxus Therapeutics Ltd., a private cancer therapeutics company. He holds a B.Sc. in Mathematics from King's College University of London and a M.Sc. in Economics from London Business School. We believe that Mr. Higgons is qualified to serve on our board of directors due to his leadership and management experience.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --